363 related articles for article (PubMed ID: 24114621)
1. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos M; Vielh P; Soria JC; Andre F
J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
[TBL] [Abstract][Full Text] [Related]
2. Epistatic interactions and drug response.
Weigelt B; Reis-Filho JS
J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
[TBL] [Abstract][Full Text] [Related]
3. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
4. Personalized oncology: genomic screening in phase 1.
Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
[TBL] [Abstract][Full Text] [Related]
5. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations and personalized medicine in melanoma: progress and future prospects.
Griewank KG; Scolyer RA; Thompson JF; Flaherty KT; Schadendorf D; Murali R
J Natl Cancer Inst; 2014 Feb; 106(2):djt435. PubMed ID: 24511108
[TBL] [Abstract][Full Text] [Related]
8. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
[TBL] [Abstract][Full Text] [Related]
9. Genomics, personalized medicine and cancer practice.
Dancey J
Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
[No Abstract] [Full Text] [Related]
10. Personalized medicine: present and future of breast cancer management.
Sabatier R; Gonçalves A; Bertucci F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
[TBL] [Abstract][Full Text] [Related]
11. Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges.
Horswell S; Matthews N; Swanton C
Cancer Lett; 2013 Nov; 340(2):220-6. PubMed ID: 23142290
[TBL] [Abstract][Full Text] [Related]
12. Recent advances and current issues in single-cell sequencing of tumors.
Sun HJ; Chen J; Ni B; Yang X; Wu YZ
Cancer Lett; 2015 Aug; 365(1):1-10. PubMed ID: 26003306
[TBL] [Abstract][Full Text] [Related]
13. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
14. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
15. Genomic medicine frontier in human solid tumors: prospects and challenges.
Dienstmann R; Rodon J; Barretina J; Tabernero J
J Clin Oncol; 2013 May; 31(15):1874-84. PubMed ID: 23589551
[TBL] [Abstract][Full Text] [Related]
16. The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice.
Marshall D; Laberge JM; Firetag B; Miller T; Kerlan RK
J Vasc Interv Radiol; 2013 Aug; 24(8):1094-103. PubMed ID: 23806383
[TBL] [Abstract][Full Text] [Related]
17. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
18. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?
Cirkel GA; Gadellaa-van Hooijdonk CG; Koudijs MJ; Willems SM; Voest EE
Future Oncol; 2014 Feb; 10(3):417-28. PubMed ID: 24559448
[TBL] [Abstract][Full Text] [Related]
19. Personalized medicine in oncology: tailoring the right drug to the right patient.
Jiang Y; Wang M
Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441
[TBL] [Abstract][Full Text] [Related]
20. Implications of intratumour heterogeneity for treatment stratification.
Crockford A; Jamal-Hanjani M; Hicks J; Swanton C
J Pathol; 2014 Jan; 232(2):264-73. PubMed ID: 24115146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]